Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

905
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
905
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

368
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
368
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

411
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
411
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.4K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

792
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
792

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RWC Update: Are We Operating Too Late on Diabetic Tractional Retinal Detachment?; Trocar-Assisted Yamane Secondary Intraocular Lens; Hemorrhagic Occlusive Retinal Vasculitis.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026
Same author

RWC Update: Are We Overtreating Wet AMD in the Anti-VEGF Era?; Unveiling Sub-Internal Limiting Membrane (ILM) Hemorrhage; Tubercular Serpiginous-Like Choroiditis.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Radiomics-based fundus autofluorescence analysis in central serous chorioretinopathy-MICRoN report number twelve.

Scientific reports·2026
Same author

Comparison of Intravitreal Antivascular Endothelial Growth Factor Therapy in Treatment-Naïve vs Panretinal Photocoagulation-Treated Eyes With Proliferative Diabetic Retinopathy.

Journal of vitreoretinal diseases·2026
Same author

Applying Lincoff's Rule to Central Serous Chorioretinopathy: The Macula Society International CSCR Research Network (MICRoN) Report-15.

Ophthalmology science·2026

Related Experiment Video

Updated: Dec 30, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.7K

Corticosteroids for Diabetic Macular Edema.

Jorge Chawan-Saad1, Max Wu2,3, Andres Wu3

  • 1Ophthalmology Department, Mexico Hospital, Costa Rican Social Security, San Jose, Costa Rica, USA.

Taiwan Journal of Ophthalmology
|January 17, 2020
PubMed
Summary

Corticosteroids are effective for diabetic macular edema (DME), especially for chronic cases or when VEGF inhibitors fail. Intravitreal corticosteroid implants offer longer action and reduced treatment burden, benefiting specific patient groups.

Keywords:
CorticosteroidsIluvienOzurdexRetisertdexamethasone implantdiabetic macular edemadiabetic retinopathyfluocinolone implanttriamcinolone acetonide

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.1K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.2K

Related Experiment Videos

Last Updated: Dec 30, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.7K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.1K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.2K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Pharmacology

Background:

  • Diabetic macular edema (DME) is a chronic condition with complex causes, involving vascular endothelial growth factor (VEGF) and inflammation.
  • Current treatments include VEGF inhibitors and corticosteroids, with varying patient responses.
  • Corticosteroids like triamcinolone acetonide (TA), dexamethasone (DEX), and fluocinolone acetonide (FA) implants are available.

Purpose of the Study:

  • To review the role and efficacy of corticosteroids in managing diabetic macular edema.
  • To compare corticosteroid treatment with anti-VEGF therapies.
  • To identify patient populations who may benefit from primary corticosteroid implant treatment.

Main Methods:

  • Review of current literature on DME treatments.
  • Analysis of corticosteroid pharmacokinetics and clinical outcomes.
  • Comparison of adverse event profiles between corticosteroids and anti-VEGF agents.

Main Results:

  • Corticosteroids are effective, particularly in chronic DME and when VEGF-driven treatments are insufficient.
  • Intravitreal corticosteroid implants offer longer duration of action and predictable pharmacokinetics, even in vitrectomized eyes.
  • Common side effects include cataracts and ocular hypertension; implant migration can occur. Corticosteroids are typically second-line treatments due to safety profiles.

Conclusions:

  • Corticosteroid implants can reduce treatment burden and are beneficial for specific DME patients, including those with long-standing disease or difficulty with frequent appointments.
  • No clear guidelines exist for switching between anti-VEGF and corticosteroid therapies.
  • Combination therapy does not show added benefit over monotherapy.